1.	Smoking Cessation Program in the Preadmission Clinic Phase: Phase IV Type: Behavioral study, Prevention Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: 07-0585-AE, Protocol# in Pfizer: GA30517W, NCT00937508
2.	STOP Study: Effectiveness of Zyban in a Clinical Population Phase: Phase IV Type: Behavioral study, Prevention Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 005/2008, NCT01015170
3.	The Pharmacogenetic Study , Readiness to Change , and Pharmacological Intervention for Smoking Cessation in Schizophrenia Phase: Phase IV Type: Behavioral study, Biomarker/Laboratory analysis, Prevention Status: Active Age: 16 to 65 Sponsor: Other Protocol IDs: MD-095-PP-05A, NCT00495352
4.	Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity Phase: Phase IV Type: Behavioral study, Prevention Status: Active Age: 16 to 45 Sponsor: Other Protocol IDs: P50DA016511, NCT00664755
5.	Chantix in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD) Phase: Phase IV Type: Behavioral study, Prevention Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: 2009-P-000444, NCT00907218
6.	Smoking Cessation for Veterans With Severe and Persistent Mental Illness Phase: Phase III, Phase II Type: Behavioral study, Prevention Status: Approved-not yet active Age: 18 to 75 Sponsor: Other Protocol IDs: NURA-001-09S, NCT00960375
7.	Impact of Smoking Cessation on Sleep - 5 Phase: Phase III, Phase II Type: Behavioral study, Prevention Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: NIDA-16427-5, R01-16427-5, DPMC, NCT00132821
8.	Pharmacogenetics, Emotional Reactivity and Smoking Phase: Phase III, Phase II Type: Behavioral study, Biomarker/Laboratory analysis, Prevention Status: Active Age: 18 to 65 Sponsor: NCI, Other Protocol IDs: 2003-1024, 1R01DA017073, NCT00507728
9.	Erlotinib Prevention of Oral Cancer (EPOC) Phase: Phase III Type: Prevention Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 2003-0824, EPOC, NCT00402779
10.	NicVAX/Placebo as an Aid for Smoking Cessation Phase: Phase III Type: Prevention Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: Nabi-4514, NIH grant # 1 RC2 DA028837-01, NCT00836199
11.	Evaluating a Telemedicine Smoking Cessation Program in Rural Primary Care Practices Phase: Phase III Type: Behavioral study, Prevention Status: Active Age: 18 and over Sponsor: NHLBI Protocol IDs: 625, HL087643-01A2, NCT00843505
12.	Yoga for Women Attempting Smoking Cessation Phase: Phase III Type: Behavioral study, Prevention Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: R21 AT003669-01, R21AT003669-01, NCT00492310
13.	Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype Phase: Phase III Type: Behavioral study, Prevention Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: Pro00013846, NCT00894166
14.	Efficacy and Safety Study of Nicotine Mint Lozenge (2mg and 4mg) in Smoking Cessation Phase: Phase III Type: Behavioral study, Prevention Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CHN-Nicotine Mint Lozenge-002, NCT00985985
15.	Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2 Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 0405-2006, NCT00400374
16.	Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor Phase: Phase II, Phase I Type: Prevention Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 0596-2004, NCT00314262
17.	Modulation of Arachidonic Acid Metabolism by Chemopreventive Agents in Smokers Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Prevention Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 2009-0804, MDA09-13-01, NCT01021215
18.	Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UCIRVINE-UCI-98-34, UCIRVINE-UCI-1998-521, NCT00330382, U01-CA-72294
19.	Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 2: Do Varenicline (Chantix) and Bupropion (Zyban) Change Alcohol Drinking? Phase: Phase II Type: Behavioral study, Prevention Status: Active Age: 21 and over Sponsor: Other Protocol IDs: HIC0702002391, R01AA015596-01, NCT00580645
20.	Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy Phase: Phase II Type: Behavioral study, Prevention Status: Active Age: 21 and over Sponsor: Other Protocol IDs: HIC0508000486, R01AA015596-01, NCT00699556
21.	Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia Phase: Phase I Type: Biomarker/Laboratory analysis, Prevention, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NU-NWU05-5-01, NWU05-5-01, NWU 05-5-01, NCT00571558
22.	Curbing Tobacco Use in Suburban and Rural Schools Phase: Phase I Type: Behavioral study, Prevention Status: Active Age: 14 to 16 Sponsor: NCI, Other Protocol IDs: 2005-0914, NCT00513097
23.	Mood Management Phone Counseling in Smoking Cessation Phase: Phase I Type: Behavioral study, Prevention Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: 1RO1DA017947, NCT00500877
24.	A Randomized Study of Sulindac in Oral Premalignant Lesions Phase: No phase specified Type: Prevention Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 04-099, NCT00299195
25.	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Phase: No phase specified Type: Behavioral study, Biomarker/Laboratory analysis, Educational/Counseling/Training, Prevention Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: KUMC-HSC-10332, 10332, KUMC-070313, NCT00666978